Pink Sheet brings fresh, meaningful opinion and analysis that goes beyond the headlines to help you navigate the complex world of compliance, legislation and policy and regulation. Our global network of over 20 analysts, industry experts and thought leaders continually track product progress from submission to approval and bring an original and objective perspective of how to anticipate challenges, minimize risks, and maximize opportunities.
A subscription to Pink Sheet provides lessons-learned and forward-looking Insights that biopharma leaders need to inform their decision making and strategic planning from a policy and regulatory perspective, and keep themselves and their companies out of trouble and in compliance.
A globally enhanced perspective on regulation, legislation, and compliance from an expanded network of analysts, journalists, and key opinion leaders who are your eyes and ears for timely, business-critical policy & regulation developments and market impacts.
A subscription will help you to stay up to date on policies that enhance, or impede the ability to bring products to market and help you comply with pharmacovigilance measures.
Pink Sheet also now publishes In-depth news and analysis of the non-prescription pharmaceutical and dietary supplement industries as well as a deep focus on the global manufacturing QA/QC rules and requirements.
Leading industry insight on a leading industry platform
Pink Sheet is published on a new user-friendly, interactive and responsive website. It allows you to access a large amount of relevant content from one place. The ability to create custom email alerts, numerous ways to refine and target search results, and simple tools to collect, send and share content allows you to tailor the service to your exact requirements.
Once you click through to content of interest, Pink Sheet will automatically display related articles, deals, companies, regions, clinical developments and other subjects on the same page. This means that you can identify, find and read the related content of interest without having to look for it, making the service a valuable time saving resource.
Subscribe today and get access to:
- Over 20 global analysts publishing real-time analysis accessible on mobile, tablet and PC.
- Real time news, analysis and opinion on regulation and reimbursement policy, legislation and compliance and the implications to the market.
- FDA Performance Tracker: proprietary data and collection of interactive charts that catalogue a product’s progress from submission to approval to keep you updated on key regulatory milestones, competitive analysis, and the latest trends.
- Monthly Drug Review Profile – in depth “look behind” FDA approval decisions with key insights on lessons learned.
- All the latest developments from the FDA and other federal health agencies, Capitol Hill and the White House.
- Expert Insights – Interviews with key executives, and policymakers, and
- commentary from thought leaders
- Global coverage of Rx and Over-the-Counter (OTC) medicines and manufacturing provide a unique perspective of all parts of the industry and how requirements by different regulatory authorities differ or overlap for more efficient product development and compliance planning.
- Intelligence from the non-prescription pharma and dietary supplement industries.
- Insightful analysis to help in complying with U.S. and international pharmaceutical manufacturing QA/QC requirements, cost cutting insights, best practice processes.
- Independent intelligence on quality control issues and daily OTC analysis.
- Scan headlines to be up on the latest, and tailor the service to your specific needs with refined targeted searches, and custom email alerts and RSS feeds so you never miss a development.
- “Ask the Analyst” exclusive client service to find out more about topics, developments, or trends to support presentations, proposals, or business critical decisions where your credibility is on the line.
To Speak with a Sales Representative:
If you would like to speak with one of our knowledgeable Sales Representatives, please reach out as follows:
- Email: PharmaNewsSales@informa.com
- Phone (US) +1 212-520-2765
- Phone (UK & Europe): +44 (0) 20 7017-4191
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.